NCT04328844 2026-03-30A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic CancersiOncturaPhase 1 Active not recruiting210 enrolled
NCT02955940 2025-12-17An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibIncyte CorporationPhase 2 Active not recruiting10 enrolled